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6.7-Difluoroquinoxaline (I) reacted with dimedone, indandione, and 3-methyl-1-phenylpyrazol-5-one in
DMSO solution in the presence of acid to form mono-substituted products IIa – c. Heating I with resorcinol
in EtOH in the presence of acid gave resorcinol derivative IId. 6.7-Difluoroquinoxaline in the presence of
base reacted with 3-methyl-1-phenylmethylpyrazol-5-one to form dipyrazolylmethane III and tetrapyrazolyl-
ethane derivative IV. Heating products IIa – c with N-methylpiperazine produced 7-methylpiperazine deriva-
tives Va – c of 2-substituted quinoxalines.
Keywords: 6.7-difluoroquinoxaline, reactions with nucleophiles.
Compounds with various types of biological activity
have been found among quinoxaline derivatives [1, 2]. The
quinoxaline derivatives quinoxidine and dioxidine have been
used as antimicrobial agents [3]. A series of condensed
quinoxalines were patented as anticancer drugs [4].
Substituted quinoxalines are synthesized either by con-
densation of the corresponding substituted o-phenylene-
diamines with 1.2-dioxo-derivatives or via substitution reac-
tions of easily displaced functional groups in the quinoxaline
core. Substitution reactions of F atoms in 6.7-difluoroquino-
xalines with various nucleophiles were reported [5]. We re-
cently described substitution reactions of hydrogen in the
heterocyclic core of unsubstituted quinoxaline by several
C-nucleophiles [6].
Herein we found that 6.7-difluoroquinoxaline (I) reacted
with CH-acids such as dimedone, indandione, and 3-methyl-
1-phenylmethylpyrazol-5-one in DMSO solution at room
temperature in the presence of acid to form mono-substituted
products IIa – c (Scheme 1).
Heating I with resorcinol in refluxing EtOH in the pres-
ence of HCl produced 4-(6.7-difluoroquinoxalin-2-yl)ben-
zene-1.3-diol (IId).
The molecular weights of compounds II as determined
by mass spectrometry agreed with the calculated values. A
characteristic diagnostic signature in the PMR spectrum of
mono-substituted products II was the presence of a separate
resonance for the proton of the pyrazine ring at
9.0 – 10.5 ppm.
It was interesting that the described reactions of I with
the C-nucleophiles did not stop at the formation of the -ad-
ducts but involved oxidation to the aromatic substitution
products during the course of the reaction:
It is noteworthy that the described transformations of
unsubstituted quinoxaline with the C-nucleophiles were sim-
ple and practically waste-free methods for producing
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mono-substituted quinoxaline derivatives with formation of
H
2
O as a result of the hydrogen substitution. The F atom in
the aromatic quinoxaline ring did not undergo substitution.
Compound I reacted differently with 3-methyl-1-phenyl-
methylpyrazol-5-one in DMSO in the presence of base.
Thus, the reaction of I with 3-methyl-1-phenylmethylpyra-
zol-5-one in DMSO in the presence of NEt
3
(TEA) produced
the known dipyrazolylmethane (III) (Scheme 2) [7] and
4-[1,2-bis(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-
(3-methyl-5-oxo-1-phenylpyrazolidin-4-yl)ethyl]-3-methyl-
1-phenyl-1.2-dihydropyrazol-5-one (IV) [8].
It is noteworthy that brief heating of IV in refluxing
DMF gave III. Product IV was transformed into III also in
DMF solution in the presence of I
2
at room temperature. The
transformation IV > III occurred also with brief heating of
the crystals at 255 – 260°C.
The formation mechanism of IV from I apparently in-
cluded the steps of nucleophilic addition of two molecules of
1-phenyl-3-methylpyrazol-5-one to the C=N bonds of quin-
oxaline to form bis-adduct I
1
(Scheme 3) and cleavage of
bis-adduct I
1
to form intermediate I
2
and subsequent trans-
formation of the latter into IV.
It is noteworthy that the synthesis of III and IV that was
reported earlier [8] was carried out via the reaction of
unsubstituted quinoxaline with 3-methyl-1-phenylpyrazol-
5-one under conditions analogous to those described in the
present work. This indicated that the F atoms located in the
6- and 7-positions of I had practically no effect on this trans-
formation.
However, the presence in the aromatic core of such labile
leaving groups as F atoms opened additional opportunities
for synthesizing quinoxaline derivatives.
It was found during the course of the present work that
products IIa – c reacted smoothly with N-methylpiperazine
at 115 – 120°C in DMF solution to form the corresponding
7-methylpiperazino-derivatives of quinoxalines Va – c in
50 – 60% yields (Scheme 4).
The molecular weights of compounds V as determined
by mass spectrometry corresponded with those calculated.
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Proof of localized F-7 substitution was obtained from
studies of
1
H,
19
F, and
13
C NMR spectra of IIa and Va. The
13
C NMR spectrum of IIa contained resonances for nodal
C-4a and C-8a as doublets of doublets as a result of coupling
with two F atoms through three and four bonds with 

C
136.32 ppm (J
CF
10.3 and 1.9 Hz) and 

C
129.31 ppm (J
CF
10.5 and 1.5 Hz). The multiplicity of nodal C-4a and C-8a
changed to doublets upon substitution of one of the F atoms.
Constant
3
J
CF
 10 Hz was preserved for only one of them.
Thus, the
13
C NMR spectrum of Va exhibited a doublet with


C
134.97 ppm (J
CF
12.9 Hz) and an unresolved singlet with


C
127.90 ppm. A weak-field doublet with 

C
134.97 ppm
was assigned to C-4a based on a 2D
1
H–
13
C HMBC experi-
ment (Fig. 1). In fact, this same C atom gave a cross-peak
with proton H-3 (

H
= 10.09 ppm) in the 2D
1
H–
13
C HMBC
spectrum. This was possible only for 7-substituted
methylpiperazine derivative Va.
Thus, the combined NMR results suggested that Va – c
were substitution products of F-7 by N-methylpiperazine.
Because products V were the principal substitution prod-
ucts from the reaction with N-methylpiperazine, it could be
assumed that the CH-acidic functional group in the 2-posi-
tion of compounds II activated F-7 of the aromatic quinoxa-
line core more toward amines.
Compounds IIa and Va, which contained a dimedone
moiety in the 2-position of the quinoxaline ring, could theo-
retically exist in several tautomeric forms (Scheme 5). The
PMR and
13
C NMR spectra lacked resonances indicating the
existence in these solvents of the hypothetical tautomer in
which dimedone C-2 had sp
3
-hybridization.
PMR spectra of IIa and Va in CDCl
3
solution gave a res-
onance for NH (or OH) as a narrow singlet that was shifted
considerably to weak field (

H
18.3 and 17.4 ppm, respec-
tively). This indicated that the molecules included a strong
intramolecular H-bond (IMHB). The slight difference of the
chemical shifts of dimedone C atoms C-1 and C-3
(

C
= 1.8 ppm for IIa and 1.3 ppm for Va) argued in favor of
tautomer K. Greater differences in the chemical shifts of the
carbonyl C atoms could be expected for tautomer E. How-
ever, an analysis of 2D
1
H–
13
C HMBC experiments was con-
sistent with the presence of both tautomeric forms K and E.
In fact, on one hand we observed cross-peaks between the
NH proton and C-3, C-4a, and C-2 that were characteristic of
tautomer K. On the other, the HMBC spectrum of IIa
showed cross-peaks between a weak-field proton and C-3
(194.35 ppm) and C-4 (48.65 ppm) that either could occur in
tautomer E or could be due to transfer of spin–spin coupling
through an IMHB in tautomer K. In both instances, the stron-
gest cross-peak corresponded to coupling of the NH proton
and C-2. However, such coupling could occur in both tauto-
meric forms.
We measured chemical shifts of
15
N through 2D
1
H–
15
N
HMQC and HMBC experiments in order to obtain additional
information about the state of the tautomeric equilibrium for
the studied compounds. In both instances, cross-peaks in
1
H–
15
N HMQC spectra that were due to direct coupling of
the NH proton and N-1 were observed. This left no doubt
that the tautomeric equilibrium was shifted toward species
K. Also, in our opinion, the measured
15
N chemical shifts for
N-1 (

N
206 and 178 ppm, respectively) were intermediate
between shifts of sp
3
- and sp
2
-hybridized N. Thus, the ranges
of
15
N chemical shifts for these instances were 120 – 150 and
290 – 350 ppm according to the literature [9].
Considering the aforementioned, it could be assumed
that tautomeric equilibrium in CHCl
3
solution was shifted to-
ward tautomer K. However, tautomeric form E contributed
noticeably to the equilibrium state.
Thus, substituents could be introduced sequentially into
different parts of the quinoxaline core and new potentially bi-
ologically active derivatives could be obtained intentionally
owing to the different lability of the H atoms in the
heterocyclic ring and the F atoms in the aromatic fragment
and the use of appropriate activation methods. Therefore,
products from substitution of one of the F atoms by amines
were of definite interest. These did in fact contain
pharmacophores analogous to those in fluoroquinolone anti-
biotics [10].
EXPERIMENTAL PART
1
H,
19
F, and
13
C NMR spectra of IIa and Va were re-
corded on a Bruker Avance-500 instrument. The internal
standard for
1
H and
13
C NMR spectra was TMS; for
19
F
NMR spectra, hexafluorobenzene. Resonances in PMR and
13
C NMR spectra for IIa and Va were assigned based on 2D
1
H–
13
C HSQC and HMBC experiments. PMR spectra of IIb
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IIa, Va
and -c and Vb and -c were recorded in DMSO-d
6
on a
DRX-400 spectrometer (FRG). Electron-impact mass spectra
(MS-EI) were obtained on a Bruker Daltronics MicrOTOF-Q
instrument at average ionizing potential 75 eV and 250°C.
Elemental analyses for the indicated empirical formulas
agreed with those calculated.
2-(6,7-Difluoroquinoxalin-2(1H)-ylidene)-5,5-dime-
thylcyclohexane-1,3-dione (IIa). Compound I (0.166 g,
1.0 mmol) and dimedone (0.160 g, 1.14 mmol) in DMSO
(1.5 mL) were stirred for 48 h at 23 – 25°C in the presence of
HCl (conc., 0.1 mL). The precipitate of IIa was filtered off
and washed with EtOH (1.5 – 2 mL). Yield 0.148 g (50%),
mp 228 – 230°C.
PMR spectrum, 
, ppm: (500.1 MHz, CDCl
3
): 18.27 (s,
1H, NH); 10.42 (s, 1H, H3); 7.85 (dd, 1H,
3
J
H,F
= 10.1,
4
J
H,F
= 8.0 Hz, H5); 7.53 (dd, 1H,
3
J
H,F
= 9.7,
4
J
H,F
= 7.5 Hz,
H8); 2.64 (m, 2H, CH
2
); 2.50 (s, 2H, CH
2
); 1.15 (s, 6H,
2  Me).
19
F NMR spectrum,
3
J
F,F
(470.5 MHz, CDCl
3
): 35.31
(ddd,
3
J
F,F
= 21.3,
3
J
H,F
= 9.7,
4
J
H,F
= 8.0 Hz, F7); 30.25 (ddd,
3
J
F, F
= 21.3,
3
J
H,F
= 10.1,
4
J
H,F
= 7.5 Hz, F6).
13
C NMR spectrum,
3
J
F,F
(125.7 MHz, CDCl
3
): 196.18
and 194.35 (C1, C3); 152.87 (dd,
1
J
C,F
= 251.4,
2
J
C,F
=
15.8 Hz, C6/C7); 150.81 (dd,
1
J
C,F
= 255.1,
2
J
C,F
= 15.2 Hz,
C6/C7); 149.19 (d,
6
J
C,F
= 2.1 Hz, C2); 148.04 (d,
6
J
C,F
= 3.4 Hz, C3); 136.32 (dd,
3
J
C,F
= 10.3,
4
J
C,F
= 1.9 Hz,
C4a); 129.31 (dd,
3
J
C,F
= 10.5,
4
J
C,F
= 1.5 Hz, C8a); 116.18
(Hz,
2
J
C,F
= 22.3,
3
J
C,F
= 2.1 Hz, C5); 108.97 (dd,
2
J
C,F
= 20.0,
3
J
C,F
= 1.3 Hz, C8); 104.85 (C2); 52.82 (CH
2
);
48.65 (CH
2
); 30.91 (C5); 28.26 (2  Me).
15
N NMR spectrum,
3
J
H,F
(50.7 MHz, CDCl
3
): 336
(N-4); 206 (N-1).
Mass spectrum, m/z (I
rel
, %): 304 [M
+
] (73).
C
16
H
14
F
2
N
2
O
2
.
2-(6,7-Difluoroquinoxalin-2(1H)-ylidene)-2H-indene-
1,3-dione (IIb). Compound I (0.083 g, 0.5 mmol) and
indandione (0.140 g, 0.98 mmol) in DMSO (1.5 mL) were
stirred for 48 h at 20 – 25°C in the presence of HCl (conc.,
0.05 mL). The resulting precipitate was filtered off and
washed with EtOH (2 mL). [6, R. p. 49].
Yield 0.066 g (44%). mp > 300°C. PMR spectrum, 
,
ppm: 7.73 (s, 4H, CH
arom
); 8.00 – 8.10 (m, 1H,
CH
arom-quinoxalin
); 8.30 – 8.36 (m, 1H, CH
arom-quinoxalin
), 9.97
(s, 1H, CH
quinoxalin
). Mass spectrum, m/z (I
rel
, %): 310 [M
+
]
(100). C
17
H
8
N
2
F
2
O
2
.
4-(6,7-Difluoroquinoxalin-2(1H)-ylidene)-3-methyl-1-
phenyl-1H-pyrazol-5(4H)-one (IIc). Compound I (0.166 g,
1.0 mmol) and pyrazolone (0.175 g, 1.0 mmol) in DMSO
(1.5 mL) were stirred for 48 h at 20 – 25°C in the presence of
HCl (0.1 mL). The resulting precipitate was filtered off and
washed with EtOH (2 mL). [7, R. p. 49].
Yield 0.160 g (47%). mp 230 – 232°C. PMR spectrum,

, ppm: 2.64 (c, 3H, CH
3
), 7.20 – 7.30 (m, 1H, CH
arom
),
7.40 – 7.50 (m, 2H, CH
arom
), 7.80 – 7.90 (m, 2H, CH
arom
),
7.90 – 8.00 (m, 1H CH
quinoxalin
), 8.00 – 8.20 (m, 1H,
CH
quinoxalin
), 9.38 (br.s, 1H, CH
quinoxalin
). Mass spectrum, m/z
(I
rel
, %): 338 [M
+
] (100). C
18
H
12
N
4
F
2
O
2
.
4-(6,7-Difluoroquinoxalin-2-yl)benzene-1,3-diol (IId).
Compound I (0.166 g, 1.0 mmol) and resorcinol (0.135 g,
1.2 mmol) in anhydrous EtOH (5 mL) were refluxed for 5 h
in the presence of HCl (conc., 0.2 mL), diluted with H
2
O
(1:1), and cooled to 15 – 20°C. The precipitate of IId was fil-
tered off. [8, R. p. 49].
Yield 0.055 g (25%). mp > 250°C. PMR spectrum
(DMSO-d
6
), 
, ppm: 6.37 (d, 1H, J 2.3 Hz, CH
arom
); 6.4 (dd,
1H, J 8.7 Hz, J 2.3 Hz, CH
arom
); 7.80 – 7.96 (m, 1H,
CH
quinoxalin
); 7.97 – 8.03 (m, 1H, CH
quinoxalin
); 8.03 (d, 1H, J
8.7 Hz, CH
arom
); 9.56 (s, 1H, CH
quinoxalin
); 9.87 (s, 1H, OH),
13.36 (s, 1H, OH). MS: m/z (I
rel
, %): 274 [M
+
] (100).
C
14
H
8
N
2
F
2
O
2
.
Reaction of I with 3-methyl-1-phenylpyrazol-5-one in
the presence of base. Compound I (0.166 g, 1.0 mmol) and
3-methyl-1-phenylpyrazol-5-one (0.522 g, 3.0 mmol) in
DMSO (2 mL) were held for 48 h at room temperature in the
presence of TEA (0.3 mL), diluted with H
2
O (1:1), and acidi-
fied with HCl solution (15%) until the pH was 5 – 6. The re-
sulting precipitate was filtered off, washed with hot EtOH
(10 mL), and dried at 100°C to afford IV (0.340 g, 47%),
mp > 250°C. The EtOH rinsings were cooled. The resulting
precipitate of III was filtered off. Yield 0.025 g (7%). Com-
pound III was identified by melting point and spectral char-
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Fig. 1. Correlations between proton H-3 and nodal C-4a that were observed in 2D
1
H–
13
C HMBC spectra of IIa (a) and Va (b ).
acteristics (PMR, MS) as dipyrazolylmethane, which was de-
scribed before [7, 8].
Transformation of IV into III
A. Compound IV (0.020 g, 0.03 mmol) was heated in
refluxing DMF (2 mL) for 5 min, cooled to room tempera-
ture, and diluted with H
2
O (1:1). The resulting precipitate of
III was filtered off, yield 0.010 g (50%).
B. Compound IV (0.020 g, 0.03 mmol) was dissolved in
DMF (1.5 mL) at room temperature, treated with I
2
(0.020 g,
0.08 mmol), held at room temperature for 24 h, and treated
with H
2
O (0.1 mL). The resulting precipitate of III was fil-
tered off, yield 0.010 g (50%).
2-[6-Fluoro-7-(4-methylpiperazin-1-yl)quinoxalin-2-
(1H)-ylidene]-5,5-dimethylcyclohexane-1,3-dione (Va).
Compound IIa (0.060 g, 0.02 mmol) in DMF (1 mL) was
heated with N-methylpiperazine (0.10 g, 1.0 mmol) at 120°C
for 2.5 – 3 h and diluted with H
2
O until crystalline Va pre-
cipitated. The precipitate of Va was filtered off and washed
with H
2
O. Yield 0.045 g (59%). mp 173 – 174°C. PMR spec-
trum (500.1 MHz, CDCl
3
), 
, ppm: 17.43 (s, 1H, NH); 10.34
(s, 1H, H3); 7.64 (d, 1H,
3
J
H,F
13.0 Hz, H-5); 6.98 (d, 1H,
4
J
H,F
8.0 Hz, H-8); 3.33 (m, 4H, H-2); 2.65 (m, 4H, H-3);
2.59 (s, 2H, H-4); 2.49 (s, 2H, H-6); 2.39 (s, 3H, NMe);
1.13 (s, 6H, 2Me). NMR spectrum
19
F (470, 5MHz, CDCl
3
)

, ppm: 44.44 (dd,
3
J
H,F
13.0,
4
J
H,F
8.0 Hz, F-6). NMR spec-
trum
13
C (125.7 MHz, CDCl
3
) 
, ppm: 197.43 and 196.16
(C-1, 3); 155.41 (d,
1
J
C,F
253.7 Hz, C-6); 147.24 (d,
6
J
C,F
1.9 Hz, C-2); 145.63 (C-3); 144.93 (d,
2
J
C,F
11.2 Hz, C-7);
134.97 (d,
3
J
C,F
12.9 Hz, C-4a); 127.90 (C-8a); 114.66 (d,
2
J
C,F
22.4 Hz, C-5); 106.46 (d, 3J
C,F
4.4 Hz, C-8); 103.40
(C-2); 54.73 (C-3); 53.01 and 50.46 (C-4,6); 50.08 (d,
4
J
C,F
5.0 Hz, C-2); 46.06 (NMe); 30.80 (C-5); 28.33
(2Me). NMR spectrum
15
N (50.7 MHz, CDCl
3
) 
, ppm:
336 (N-4); 178 (N-1); 66 (N-1); 37 (N-4). Mass spectrum,
m/z (I
rel
, %): 384 [M
+
] (36), 70 (100). C
21
H
25
N
4
FO
2
.
2-[6-Fluoro-7-(4-methylpiperazin-1-yl)quinoxalin-2(1H)-
ylidene]-2H-indene-1,3-dione (Vb). Compound IIb
(0.021 g, 0.07 mmol) in DMF (1 mL) was heated with
N-methylpiperidine (0.10 g, 1.0 mmol) at 120°C for 2.5 – 3 h
and filtered. The mother liquor was evaporated to dryness in
vacuo. The solid was worked up with H
2
O (1.5 – 2 mL). The
residue of Vb was filtered off and washed with H
2
O
(1.5 – 2 mL). Yield 0.16 g (61%). mp > 250°C. PMR spec-
trum, 
, ppm: 2.33 (s, 3H, CH
3
), 2.60 – 2.62 (m. 4H,
2CH
2
), 3.32 – 3.34 (m. 4H, 2CH
2
), 7.50 – 7.56 (m, 1H,
CH
quinoxalin
); 7.63 (m, 4H, CH
arom
); 7.62 – 7.65 (m, 1H,
CH
quinoxalin
), 9.75 (s, 1H, CH
quinoxalin
), 13.50 (br.s 1H, NH).
Mass spectrum, m/z (I
rel
, %): 384 [M
+
] (36), 70 (100).
C
22
H
19
N
4
FO
2
.
4-[6-Fluoro-7-(4-methylpiperizin-1-yl)quinoxalin-2-
(1H)-ylidene]-3-methyl-1-phenyl-(1H)-pyrazol-5(4H)-one
(Vc). Compound IIc (0.067 g, 0.2 mmol) in DMF (1 mL)
was heated with N-methylpiperazine (0.10 g, 1.0 mmol) at
120°C for 2.5 – 3 h and diluted with H
2
O until crystalline Vc
precipitated. The precipitate of Vc was filtered off and
washed with H
2
O. Yield 0.43 g (53%). mp 220 – 221°C.
PMR spectrum, (DMSO-d
6
), 
, ppm: 2.32 (s, 3H, CH
3
), 2.53
(s. 3H, CH
3
), 2.58 – 2.60 (m. 4H, 2CH
2
), 3.30 – 3.33 (m.
4H, 2CH
2
), 7.10 – 7.35 (m, 1H, CH
arom-quinoxalin
);
7.33 – 7.40 (m, 2H, CH
arom
); 7.50 – 7.54 (m, 1H,
CH
arom-quinoxalin
), 8.00 – 8.03 (m, 2H, CH
arom
), 8.97 (s, 1H,
CH
quinoxalin
). Mass spectrum, m/z (I
rel
, %): 418 [M
+
] (47), 70
(100). C
23
H
23
N
6
FO.
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